Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

CIBC World Keeps 'Strong Buy' on Andrx


CIBC World reiterates strong buy on Andrx (ADRX).

Analyst Elliot Wilbur says, having received FDA approval, Andrx will be one of only three generic makers of K-Dur, Schering-plough's treatment for cardiovascular disease. He notes Andrx will launch its product immediately, slightly ahead of his late second quarter assumption. Wilbur says K-Dur is a $275 million potassium supplement; and he believes 2002 sales of Andrx's product could approach $20 million, although his model assumes only $10 million. He says Andrx is on track to generate $2.00 2002 EPS, excluding any contribution from a generic form of ulcer drug Prolosec.


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus